Clinical Trials Browser

Phase 1 × Neoplasm Metastasis × IFL protocol × Clear all

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

Phase 1 Terminated

272 enrolled

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT05087992 2025-02-19

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

Phase 1 Completed

13 enrolled 17 charts

Gastrointestinal

Gastrointestinal Neoplasms, Neoplasm Metastasis

NCT02726334 2019-01-16

A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

Phase 1 Terminated

22 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00719199 2013-10-22

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer

Phase 1 Terminated

21 enrolled

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

Clinical Trials

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

A Study to Find the Best Dose of BI 905711 in Combination With Chemotherapy and to Test Whether This Dose Helps People With Advanced Gastrointestinal Cancers

A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer